Phase 4 N=50 Effect of Locally-Applied Simvastatin on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients
Periodontal Diseases
Primary: Change in Clinical Attachment Level (CAL) — 7.0; 6.9 millimeters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=1,211 Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents With Severe, Uncontrolled Asthma
Asthma
Primary: Exposure Adjusted Incidence Rates of AEs/SAEs — 49.62; 62.66; 47.15; 69.97 Patients with AEs per 100 person-years
Phase 2 N=37 Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer
Esophageal Cancer · Gastric Cancer
Primary: Percentage of Participants With Progression Free Survival — 70 percentage of participants with PRS
Phase 3 N=630 A Study to Evaluate the Safety and Efficacy of IPX203 in Parkinson's Disease Participants With Motor Fluctuations
Parkinson's Disease (Disorder)
Primary: Mean Change From Baseline in "Good on" Time Per Day at Week 20/Early Termination (ET) — 11.67; 11.72; -0.39; -0.97 hours/day — p=0.0194
Phase 2 N=79 Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma
Cutaneous Squamous Cell Carcinoma
Primary: Number of Participants With Pathologic Complete Response (pCR) as Assessed by Independent Central Pathology Review — 40 Participants
N/A N=60 Reinforcement Learning in Diabetes Mellitus Trial
Diabetes Mellitus, Type 2 · Medication Adherence
Primary: Medication Adherence — 74; 68 pill bottle openings
Phase 2 N=31 Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival (PFS) After Treatment With Doxil, Carboplatin and Bevacizumab in Patients With ER, PR, HER2neu Negative Metastatic Breast Cancer — 6 participants
Phase 2 N=91 A Clinical Trial of Intravenous (IV) Ganaxolone in Women With Postpartum Depression
Depression · Depressive Disorder · Depression, Postpartum
Primary: Change From Baseline in Hamilton Depression Rating Scale 17-item Version (HAMD17) Total Score — -13.0; -12.0; -14.0; -14.3 Scores on a scale
Phase 4 N=20 Esophageal Food Impaction
Esophageal Food Bolus Obstruction
Primary: Patients Condition at Discharge — 2; 15 Participants
N/A N=88 Conducting Annual Asthma Reviews Using Telehealthcare: Comparison With Standard Care (Face-to-face Consultations)
Asthma
Primary: Patient Experience: Overall Patient Experience Score (General Practice Assessment Questionnaire GPAQ Score) — 390.0; 400.0 score on a scale — p=0.510
N/A N=60 Feasibility of Light Therapy for Fatigue N-of-1 Trials
Fatigue
Primary: Mean System Usability Score (SUS). — 78.89 score on a scale
Phase 3 N=5,404 Pivotal Phase 2b/3 ALVAC/Bivalent gp120/MF59 HIV Vaccine Prevention Safety and Efficacy Study in South Africa
HIV Infections
Primary: Incidence Rate of HIV-1 Infection Diagnosed After Enrollment (Concurrent With First Vaccination) Through 24 Months After Enrollment — 0.034; 0.033; 0.034; 0.033 events…
N/A N=49 Managing Asthma Patients With AMAZE™: A Novel Disease Management Platform
Asthma
Primary: Number of Days Participants Accessed the AMAZE™ App (Weeks 1 to 4) — 16.8; 16.5; 2.3; 2.2 Days
Phase 2 N=61 A Study of Ixazomib+Daratumumab+Dexamethasone (IDd) in Relapsed and/or Refractory Multiple Myeloma (RRMM)
Multiple Myeloma
Primary: Percentage of Participants With Very Good Partial Response (VGPR) or Better (Complete Response + VGPR) — 32.2 percentage of participants
N/A N=47 Novel Application of Simulation for Providers to Overcome Decisional Gaps in High-risk Prescribing
Medication Administered in Error · Antipsychotics and Neuroleptics Toxicity
Primary: High-risk Medication Doses — 0.049; 0.052; 0.036; 0.019 No. of med orders by patient per intern